{"nctId":"NCT00382031","briefTitle":"Zalutumumab in Patients With Non-curable Head and Neck Cancer","startDateStruct":{"date":"2006-11"},"conditions":["Head and Neck Cancer","Squamous Cell Cancer"],"count":286,"armGroups":[{"label":"zalutumumab","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Zalutumumab","Other: Control"]},{"label":"Control","type":"OTHER","interventionNames":["Other: Control"]}],"interventions":[{"name":"Zalutumumab","otherNames":["Zalutumumab in combination with Best Supportive Care"]},{"name":"Control","otherNames":["Best Supportive Care"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Males and Females age â‰¥ 18 years\n2. Confirmed diagnosis, initially or at relapse, of squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx, considered incurable with standard therapy\n3. Failure to at least one course of standard platinum-based chemotherapy\n\nExclusion Criteria:\n\n1. Three or more chemotherapy regimens other than platinum-based chemotherapy\n2. Prior treatment with EGFr antibodies and/or EGFr small molecule inhibitors\n3. Past or current malignancy other than SCCHN, except for certain other cancer diseases","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":"A patient's overall survival was defined as the time from the date of randomization until the date of death from any cause, assessed up to 41 months. Overall survival was censored if the patient was lost to follow-up or refused to continue in the trial.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":null},{"groupId":"OG001","value":"5.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Objective Tumor Response","description":"Objective tumor response assessed according to Response Evaluation Criteria in Solid Tumours (RECIST v 1.0) J Natl Cancer Inst 2000;92:205-16 assessed by CT/MRI. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the longest diameter of target lesions; Overall Response (OR), CR+PR","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response","description":"Duration of response defined as the time from the first date where measurement criteria for complete or partial response (whichever status is recorded first) are met until the first date that death, recurrence or progressive disease is objectively documented.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":null},{"groupId":"OG001","value":"7.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS)","description":"PFS (defined as the time from randomization until disease progression or death). The progression events were defined by well-documented and verifiable imaging data. In case of censoring, the date of censoring had to be the last time point documenting the status of the patient.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":null},{"groupId":"OG001","value":"8.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":180,"n":189},"commonTop":["General disorders and administration site conditions","Skin and subcutaneous tissue disorders","Gastrointestinal disorders","Respiratory, thoracic and mediastinal disorders","Infections and Infestations"]}}}